Active treatment at the end of life-importance of palliative care in advanced non-small cell lung cancer: a cohort study.

Background: Palliative care focuses on improving the quality of life and comfort of patients in the last stages of their disease by providing relief for pain and other distressing symptoms, and it integrates physical, psychological, and spiritual aspects. The main objective of this study is to assess the impact of palliative care in the administration of active treatment during the last 3 weeks of life of patients with advanced non-small cell lung cancer (NSCLC) and its impact on survival after the last treatment cycle.

Methods: A retrospective study was conducted across two centers, analyzing data from both sites to evaluate outcomes and trends in patient care. It includes 118 deceased patients who had been diagnosed with NSCLC between 1/1/2019 and 30/4/2024. The patients had received at least one cycle of active treatment with chemotherapy, immunotherapy, or both. Patients with druggable mutations in their first line were excluded.

Results: Overall survival (OS) after the last cycle was 56 days in the patients treated by the palliative care unit [95% confidence interval (CI): 41.6-70.4] vs. 27 days for those who were not treated by the unit (95% CI: 19.4-34.5) (Plog-rank<0.001); hazard ratio (HR) 3.23 (95% CI: 2.01-5.13) (P<0.001). In patients ≥75 years old, survival after the last cycle was 47 days (95% CI: 33.9-60.1) vs. 34 days (95% CI: 24.9-43.1) for those <75 years old (Plog-rank<0.001). In patients with ECOG 2, the survival after the last cycle was 56 days for those assessed by the palliative care unit (95% CI: 42.9-69.1) vs. 23 days (95% CI: 19.5-26.5) for those who had not been assessed (Plog-rank<0.001). In patients who had been assessed by the palliative care unit, the odds ratio (OR) to receive treatment in the last 3 weeks of life was 0.20 (95% CI: 0.07-0.57) (P=0.002). In patients under 75 years old, the OR was 2.83 (95% CI: 1.03-7.72) (P=0.042).

Conclusions: The assessment by multidisciplinary teams that integrate palliative care doctors has a significant impact on the decision to withhold active treatment over the last 3 weeks of life in patients with advanced NSCLC. The greatest benefit is observed in patients with performance status measured by Eastern Cooperative Oncology Group (ECOG) ≥2.